Shulamit Ron-Bigger
Chief Operating Officer at Aktis Oncology, Inc.
Network origin in Shulamit Ron-Bigger first degree
Entity | Entity type | Industry | |
---|---|---|---|
Aktis Oncology, Inc.
Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020.
7
| Holding Company | Medical/Nursing Services | 7 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Shulamit Ron-Bigger via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal | |
Biotechnology Value Fund LP
Biotechnology Value Fund LP Investment ManagersFinance Part of BVF, Inc., Biotechnology Value Fund LP is an Alternative Investment Manager. The company is based in San Francisco, CA. | Investment Managers | Corporate Officer/Principal | |
BVF Partners LP
BVF Partners LP Investment ManagersFinance BVF Partners LP (BVF) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded in 1993 and is a subsidiary of BVF, Inc. BVF provides discretionary advisory services to private investment vehicles which includes commingled limited partnerships (the BVF Funds) and a limited liability entity organized for a single investor (Single Investor Fund) as well as to separately managed accounts. | Investment Managers | Corporate Officer/Principal | |
UBS Securities LLC
UBS Securities LLC Investment ManagersFinance UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients. | Investment Managers | Analyst-Equity | |
JPMorgan Securities LLC
JPMorgan Securities LLC Investment ManagersFinance JPMorgan Securities LLC (JPMS) is a securities brokerage firm headquartered in New York City. The firm was founded in 1985 and is a subsidiary of JPMorgan Broker-Dealer Holdings, Inc., ultimately held by JPMorgan Chase & Co., Inc. (NYSE: JPM). JPMS provides research on fixed income, credit, derivatives, emerging markets, foreign exchange, structured finance, technical analysis and bond indices. Their equity analysts cover equities throughout North America, EMEA, Asia/Pacific and the emerging markets. The firm's fixed income team formulates trading and portfolio recommendations for investors in global bonds and other fixed-income markets based on valuations, analytics and market dynamics. | Investment Managers | Analyst-Equity | |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
ANAPTYSBIO, INC. | Biotechnology | Director/Board Member | |
IlluminOss Medical, Inc.
IlluminOss Medical, Inc. Medical SpecialtiesHealth Technology IlluminOss Medical, Inc. engages in the designing, developing, and marketing of orthopedic fracture repair products. The company was founded by Robert A. Rabiner and Arnold-Peter C. Weiss in 2007 and is headquartered in East Providence, RI. | Medical Specialties | Director/Board Member | |
Harvest Automation, Inc.
Harvest Automation, Inc. Trucks/Construction/Farm MachineryProducer Manufacturing Harvest Automation, Inc. designs and produces robotics for manual labor applications. It enables growers to create a sustainable workforce of robots working safely alongside people to increase efficiency, reliability and plant quality. The firm’s robots are powering the next innovation surge in agriculture and has engineered the first practical, scalable robots for a range of agricultural applications. The company was founded by Clara Vu, Paul E. Sandin, Charles M. Grinnell and Joseph L. Jones in 2008 and is headquartered in Billerica, MA. | Trucks/Construction/Farm Machinery | Director/Board Member | |
Clinical Ink, Inc.
Clinical Ink, Inc. Internet Software/ServicesTechnology Services Clinical Ink, Inc. provides electronic source solutions for clinical research sites. Its solutions include data management, monitoring, clinical sites and patient centric. The company was founded by Douglas E. Pierce Jr. and Tommy Littlejohn on July 19, 2006 and is headquartered in Winston-Salem, NC. | Internet Software/Services | Director/Board Member | |
RHYTHM PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
Rhythm Therapeutics, Inc. | Biotechnology | Director/Board Member | |
Tetherex Pharmaceuticals Corp.
Tetherex Pharmaceuticals Corp. BiotechnologyHealth Technology Tetherex Pharmaceuticals Corp. operates as a biopharmaceutical company. It focuses on development of therapeutics for the treatment of thrombosis, inflammation and tumor metastasis across a broad range of severe diseases. The company was founded by Rodger P. McEver and Richard D. Cummings and is headquartered in Oklahoma City, OK. | Biotechnology | Director/Board Member | |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact LLC (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
Brandeis University | College/University | Undergraduate Degree Undergraduate Degree | |
AVEO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Georgetown University | College/University | Graduate Degree Undergraduate Degree | |
ADDEX THERAPEUTICS LTD | Pharmaceuticals: Major | Director/Board Member | |
Seahorse Bioscience, Inc.
Seahorse Bioscience, Inc. Medical SpecialtiesHealth Technology Seahorse Bioscience, Inc. provides metabolic analyzers and stress kits. Its medical device is use to determine a new therapeutic approach in treating acute myeloid leukemia. The company was founded on November 2, 2000 and is headquartered in Billerica, MA. | Medical Specialties | Director/Board Member | |
OSS, Inc.
OSS, Inc. Information Technology ServicesTechnology Services OSS, Inc. provides information technology services. It operates as a global management consulting, technology services and systems integration leader in business. The firm offers software development, IT staff augmentation, technical support, and training services. The company was founded in 1992 and is headquartered in Gaithersburg, MD. | Information Technology Services | Director/Board Member | |
BioNJ, Inc.
BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Miscellaneous Commercial Services | Director/Board Member | |
Harvard Medical School | College/University | Doctorate Degree | |
PROTHENA CORPORATION PLC | Biotechnology | Director/Board Member Director/Board Member | |
EcoR1 Capital, LLC
EcoR1 Capital, LLC Investment ManagersFinance EcoR1 Capital LLC (EcoR1) is an independent registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Oleg Nodelman in 2012. EcoR1 serves as the general partner of and investment adviser to investment funds and provides investment advice to separate account clients. | Investment Managers | Chief Executive Officer | |
Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
OSS Healthcare, Inc. | Director/Board Member | ||
EVELO BIOSCIENCES, INC. | Pharmaceuticals: Major | Private Equity Investor | |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
REPARE THERAPEUTICS INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Switch Bio, Inc.
Switch Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Switch Bio, Inc. is an American company that focuses on research and development in the field of gene therapy. The private company is based in Boston. | Miscellaneous Commercial Services | Director/Board Member | |
CODA Biotherapeutics, Inc.
CODA Biotherapeutics, Inc. Medical SpecialtiesHealth Technology CODA Biotherapeutics, Inc. engages in the development of chemo genetic neuromodulation platform for the treatment of severe neurological disorders. The company was founded by Mitchell H. Finer, Allan Basbaum, Nicholas Boulis, Joseph Glorioso III and Kenneth P. Greenberg in 2014 and is headquartered in South San Francisco, CA. | Medical Specialties | Director/Board Member | |
ENTRADA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
EcoR1 Panacea Holdings LLC | Chief Executive Officer | ||
Nextpoint Therapeutics, Inc.
Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Director/Board Member | |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Biotechnology | Director/Board Member | |
TURMERIC ACQUISITION CORP. | Financial Conglomerates | President Chairman | |
NUVATION BIO INC. | Biotechnology | Director/Board Member | |
PANACEA ACQUISITION CORP. II | Financial Conglomerates | Chief Executive Officer | |
Crossbow Therapeutics, Inc.
Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Pharmaceuticals: Major | Director/Board Member | |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Director/Board Member Founder | |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
VALERITAS INC | Medical Specialties | Director/Board Member | |
Paratus Sciences Corp.
Paratus Sciences Corp. BiotechnologyHealth Technology Paratus Sciences Corp. is an American company that focuses on unlocking the secrets of bat biology. The company's main goal is to elucidate novel insights and identify new therapeutic targets. The company was founded by Thomas Zwaka, Richard Young, Paul Matsudaira. The CEO is Amir H. Nashat. | Biotechnology | Director/Board Member |
Statistics
International
United States | 47 |
Canada | 3 |
Switzerland | 2 |
Ireland | 2 |
Sectoral
Health Technology | 28 |
Finance | 11 |
Consumer Services | 5 |
Commercial Services | 4 |
Technology Services | 3 |
Operational
Director/Board Member | 76 |
Corporate Officer/Principal | 18 |
Independent Dir/Board Member | 13 |
Chief Executive Officer | 10 |
Private Equity Investor | 10 |
Most connected contacts
Insiders | |
---|---|
Todd Foley | 38 |
Helen Kim | 34 |
Lloyd Segal | 19 |
Matt Roden | 18 |
Oleg Nodelman | 15 |
Brian Goodman | 8 |
Lloyd Segal | 1 |
- Stock Market
- Insiders
- Shulamit Ron-Bigger
- Company connections